首页> 美国卫生研究院文献>Oncotarget >Circumvent the uncertainty in the applications of transcriptional signatures to tumor tissues sampled from different tumor sites
【2h】

Circumvent the uncertainty in the applications of transcriptional signatures to tumor tissues sampled from different tumor sites

机译:规避在从不同肿瘤部位取样的肿瘤组织中转录签名应用的不确定性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The expression measurements of thousands of genes are correlated with the proportions of tumor epithelial cell (PTEC) in clinical samples. Thus, for a tumor diagnostic or prognostic signature based on a summarization of expression levels of the signature genes, the risk score for a patient may dependent on the tumor tissues sampled from different tumor sites with diverse PTEC for the same patient. Here, we proposed that the within-samples relative expression orderings (REOs) based gene pairs signatures should be insensitive to PTEC variations. Firstly, by analysis of paired tumor epithelial cell and stromal cell microdissected samples from 27 cancer patients, we showed that above 80% of gene pairs had consistent REOs between the two cells, indicating these REOs would be independent of PTEC in cancer tissues. Then, by simulating tumor tissues with different PTEC using each of the 27 paired samples, we showed that about 90% REOs of gene pairs in tumor epithelial cells were maintained in tumor samples even when PTEC decreased to 30%. Especially, the REOs of gene pairs with larger expression differences in tumor epithelial cells tend to be more robust against PTEC variations. Finally, as a case study, we developed a gene pair signature which could robustly distinguish colorectal cancer tissues with various PTEC from normal tissues. We concluded that the REOs-based signatures were robust against PTEC variations.
机译:数千种基因的表达测量结果与临床样本中肿瘤上皮细胞(PTEC)的比例相关。因此,对于基于特征基因表达水平的总结的肿瘤诊断或预后特征,患者的风险评分可能取决于从不同肿瘤部位取样的肿瘤组织,并且该患者具有不同的PTEC。在这里,我们建议基于样本内的相对表达顺序(REO)的基因对签名对PTEC变异不敏感。首先,通过对来自27位癌症患者的肿瘤上皮细胞和基质细胞显微解剖样本进行配对分析,我们发现超过80%的基因对在两个细胞之间具有一致的REO,这表明这些REO在癌症组织中将独立于PTEC。然后,通过使用27个配对样本中的每个样本模拟具有不同PTEC的肿瘤组织,我们显示,即使PTEC降至30%,在肿瘤样本中仍保留了约90%的肿瘤上皮细胞基因对的REO。尤其是,在肿瘤上皮细胞中具有较大表达差异的基因对的REO倾向于对PTEC变异更有抵抗力。最后,作为案例研究,我们开发了一种基因对签名,可以强有力地区分具有各种PTEC的结直肠癌组织与正常组织。我们得出的结论是,基于REO的签名对PTEC的变化具有鲁棒性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号